Welcome to our dedicated page for Oruka Therapeutics news (Ticker: ORKA), a resource for investors and traders seeking the latest updates and insights on Oruka Therapeutics stock.
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is a clinical-stage biotechnology company developing novel biologics for chronic skin diseases, and its news flow reflects the progress of a focused dermatology pipeline. Company press releases highlight advances for its lead monoclonal antibodies ORKA-001 and ORKA-002, both engineered to target key immunology pathways in plaque psoriasis and related conditions while enabling infrequent dosing.
News updates frequently cover clinical milestones such as Phase 1 interim data, initiation and enrollment of Phase 2 trials, and detailed designs of the EVERLAST-A and EVERLAST-B studies of ORKA-001 in moderate-to-severe plaque psoriasis. Oruka also reports on the first-in-human trial of ORKA-002, including pharmacokinetic and pharmacodynamic findings that support potential twice-yearly dosing in psoriasis and quarterly dosing in hidradenitis suppurativa.
In addition to pipeline developments, Oruka’s news includes quarterly financial results, corporate updates, and capital-raising activities, such as a private placement financing described in company communications. Governance and leadership items, including board appointments and executive promotions, are disclosed through both press releases and Form 8-K filings. The company also announces participation in major healthcare and investor conferences, where it presents clinical data and corporate overviews.
Investors and observers following ORKA news can expect coverage of clinical trial data readouts, regulatory milestones such as IND clearance, financing transactions, and changes in leadership or board composition. This page aggregates those updates so readers can monitor how Oruka’s psoriatic disease programs and broader antibody portfolio evolve over time.
Oruka Therapeutics (Nasdaq: ORKA) priced an upsized underwritten public offering of 9,660,000 common shares at $72.50 per share, expected to raise approximately $700.4 million in gross proceeds before underwriting discounts, commissions and offering expenses.
The company granted underwriters a 30‑day option to purchase up to an additional 1,449,000 shares. The offering is expected to close on or about April 30, 2026, subject to customary closing conditions. A shelf registration on Form S‑3 became effective on April 10, 2026.
Oruka Therapeutics (Nasdaq: ORKA) announced a proposed underwritten public offering of $500 million of common stock and, for certain investors, pre-funded warrants, with a 30-day underwriter option to purchase up to an additional $75 million. The offering is subject to market and other conditions and may not be completed.
Joint bookrunners include Leerink Partners, TD Cowen, Goldman Sachs, Stifel and Guggenheim; a Form S-3 shelf registration became effective April 10, 2026.
Oruka Therapeutics (NASDAQ: ORKA) reported positive interim EVERLAST-A Phase 2a results for ORKA-001 in moderate-to-severe plaque psoriasis. At Week 16, 63.5% (40/63) achieved PASI 100; PASI 90 83%; IGA 0/1 84%. Safety was comparable to placebo with no serious TEAEs; TEAE rates were 51% (ORKA-001) vs 57% (placebo). Updated Phase 1 PK/PD data showed concentrations above effective trough levels for a year, supporting potential annual dosing. Longer-term Week 28 and 52 follow-up data expected in 2H 2026; Phase 2b EVERLAST-B data expected in 2027. Webcast held April 27, 2026 at 8:00 a.m. ET.
Oruka Therapeutics (Nasdaq: ORKA) will report Week 16 data for ORKA-001 from the ongoing EVERLAST-A Phase 2a trial in moderate-to-severe plaque psoriasis on April 27, 2026.
The company will host a live conference call and webcast at 8:00 a.m. ET; a replay will be available afterward. Access via the Investors section at https://ir.orukatx.com/news-events/events-presentations.
Oruka Therapeutics (Nasdaq: ORKA) reported Q4 and full-year 2025 results and a pipeline update. The company had $479.6 million in cash and marketable securities as of December 31, 2025. EVERLAST-A enrollment completed; Week 16 data now expected in 2Q 2026. ORCA-SURGE Phase 2 for ORKA-002 initiated, with data expected in 2027. Full-year 2025 R&D expense was $100.6 million and net loss was $105.4 million. ORKA-002 Phase 1 interim data showed ~75–80 day half-life, supporting twice-yearly maintenance dosing.
Oruka Therapeutics (Nasdaq: ORKA) announced participation and presentations at multiple investor conferences in February–March 2026, including Guggenheim Emerging Outlook, TD Cowen, UBS Biotech Summit Miami, Jefferies Biotech on the Beach, Leerink Global Healthcare, and Barclays Global Healthcare.
Presentation dates and times are listed; a webcast and replay will be available on the Oruka investor events website.
Oruka Therapeutics (Nasdaq: ORKA) reported positive interim Phase 1 data for ORKA-002 and trial updates for ORKA-001 on Jan 12, 2026. ORKA-002 showed a 75–80 day half-life, >3x that of bimekizumab, and comparable Cmax, supporting pharmacokinetic modeling for twice-yearly maintenance dosing in plaque psoriasis and quarterly dosing in hidradenitis suppurativa. The Phase 1 (n=24) safety profile was favorable with no severe or serious TEAEs. Oruka plans a ~160-patient Phase 2 ORCA-SURGE psoriasis trial in 1H 2026 and a Phase 2 HS trial in 2H 2026. EVERLAST-B for ORKA-001 dosed first patients in Dec 2025 with data expected in 2027.
Oruka Therapeutics (Nasdaq: ORKA) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco from January 12-15, 2026. Oruka's presentation is scheduled for Thursday, January 15, 2026 at 9:00 AM PT. A live webcast and replay will be available on the company's investor events website.
The company is a clinical-stage biotechnology firm developing novel biologics for chronic skin diseases including plaque psoriasis. Investors can access the webcast and replay via Oruka's investor events page.
Oruka Therapeutics (Nasdaq: ORKA) announced a board transition on December 11, 2025: Chris Martin was appointed to the Board and Cameron Turtle, DPhil, resigned effective the same date.
Mr. Martin brings 25+ years of commercial experience across sales, marketing, market access, commercial operations, and business development and most recently served as Chief Commercial Officer at Verona Pharma, which was acquired by Merck in October 2025 for approximately $10B. Oruka said Martin's expertise will support late‑stage development and commercialization planning for its co‑lead programs ORKA-001 and ORKA-002.
Oruka Therapeutics (Nasdaq: ORKA) reported Q3 2025 results and a corporate update highlighting clinical progress and a strengthened balance sheet. Key clinical readouts: ORKA-001 Phase 1 interim data showed a ~100-day half-life (>3x risankizumab) and sustained STAT3 inhibition, supporting potential once-per-year dosing. ORKA-001 Phase 2a (EVERLAST-A) is enrolling with PASI 100 Week 16 data expected 2H 2026; EVERLAST-B dosing planned 1H 2026. ORKA-002 Phase 1 data expected around year-end 2025 and Phase 2 planned 1H 2026. Cash, cash equivalents, and marketable securities totaled $500.9M as of Sept 30, 2025.